VANCOUVER, BC, April 13, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 (“Q2 2023” and “first six months”). “We are excited about our…


Previous articleatai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
Next articlePT405 – The Psychedelic Medicine PAC: The Push for Federal Funding and Politicians Who Will Fight for Us